Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery.
| Title: | Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery. |
|---|---|
| Authors: | Parlar AI; Cardiovascular Surgery Clinic, Ahi Evren Gogus Kalp Damar Cerrahisi Education and Research Hospital, Trabzon - Turkey.; Sayar U; Cevirme D; Yuruk MA; Mataraci I |
| Source: | The International journal of artificial organs [Int J Artif Organs] 2014 Apr; Vol. 37 (4), pp. 344-7. Date of Electronic Publication: 2014 Feb 07. |
| Publication Type: | Case Reports; Journal Article |
| Language: | English |
| Journal Info: | Publisher: SAGE Publishing Country of Publication: United States NLM ID: 7802649 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1724-6040 (Electronic) Linking ISSN: 03913988 NLM ISO Abbreviation: Int J Artif Organs Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2018- : Thousand Oaks, CA : SAGE Publishing; Original Publication: Milano : Wichtig Editore |
| MeSH Terms: | Extracorporeal Membrane Oxygenation*/adverse effects ; Drug Substitution*; Anticoagulants/*adverse effects ; Heart Valve Prosthesis Implantation/*adverse effects ; Heparin/*adverse effects ; Mitral Valve/*surgery ; Polysaccharides/*therapeutic use ; Thrombocytopenia/*chemically induced; Thrombocytopenia/blood ; Thrombocytopenia/diagnosis ; Device Removal ; Female ; Fondaparinux ; Humans ; Reoperation ; Time Factors ; Treatment Outcome ; Young Adult |
| Abstract: | In patients with respiratory failure and impairment of the left ventricle, arteriovenous extracorporeal membrane oxygenation (ECMO) offers further therapeutic options. Systemic anticoagulation is mandatory and heparin is routinely administrated. However, repeated exposure to heparin may cause heparin-induced thrombocytopenia (HIT) and carries a risk of thrombotic mortality and morbidity. We present a patient who developed HIT during ECMO support and was treated successfully and safely by fondaparinux. Fondaparinux can be used for thromboembolic treatment or prophylaxis in a patient with HIT. |
| Substance Nomenclature: | 0 (Anticoagulants); 0 (Polysaccharides); 9005-49-6 (Heparin); J177FOW5JL (Fondaparinux) |
| Entry Date(s): | Date Created: 20140313 Date Completed: 20141229 Latest Revision: 20181202 |
| Update Code: | 20260130 |
| DOI: | 10.5301/ijao.5000302 |
| PMID: | 24619895 |
| Database: | MEDLINE |
Case Reports; Journal Article